Root James C, Campbell Claudine, Rocha-Cadman Xiomara, Kasven-Gonzalez Nicole, Maloy Molly, Flynn Jessica, Devlin Sean M, Jakubowski Ann A
Department of Psychiatry and Behavioral Sciences, Weill Cornell Medical College, New York, New York.
Department of Neurology, Weill Cornell Medical College, New York, New York.
Biol Blood Marrow Transplant. 2020 Aug;26(8):1497-1504. doi: 10.1016/j.bbmt.2020.05.010. Epub 2020 May 21.
Patients presenting for treatment of hematologic cancers may be at increased risk for cognitive dysfunction before allogeneic hematopoietic stem cell transplantation (HSCT) due to advanced age, previous chemotherapy treatment, deconditioning, and fatigue. Cognitive dysfunction may affect treatment decision making, ability to recall or follow post-HSCT treatment recommendations and overall survival (OS). A total of 448 patients admitted for HSCT between 2011 and 2014 were administered the Montreal Cognitive Assessment (MoCA) by occupational therapists during admission before transplantation, and 260 were reassessed following transplantation and before discharge. We examined select predictor variables, including age, Karnofsky Performance Status, sex, disease type, psychotropic medications, and select outcome variables, including OS, and nonrelapse mortality (NRM). Before transplantation, 36.4% of patients met criteria for cognitive dysfunction. Age was found to be a significant predictor, along with disease type (myelodysplastic syndrome [MDS], myeloproliferative disorder [MPD]). No significant association was found between cognitive dysfunction and OS or NRM. Longitudinal analysis from pretransplantation to post-transplantation indicated significant decline following HSCT. Notably, one-third of the study cohort showed cognitive dysfunction at hospital discharge. A significant proportion of HSCT candidates present with cognitive dysfunction, with older patients and those diagnosed with MDS and MPD at greatest risk in this cohort. Attention to cognitive dysfunction before transplantation may alert the treatment team to high-risk cases that require increased oversight, inclusion by caregivers, and referral to occupational therapy at discharge. Longitudinal follow-up studies are needed to clarify the specific effect of HSCT on cognitive dysfunction and the impact of cognitive dysfunction on transplantation outcomes.
因年龄较大、既往接受过化疗、身体机能下降和疲劳等因素,接受血液系统癌症治疗的患者在异基因造血干细胞移植(HSCT)前出现认知功能障碍的风险可能会增加。认知功能障碍可能会影响治疗决策、回忆或遵循HSCT后治疗建议的能力以及总生存期(OS)。2011年至2014年间,共有448名因HSCT入院的患者在移植前入院时由职业治疗师进行了蒙特利尔认知评估(MoCA),其中260名患者在移植后及出院前进行了重新评估。我们研究了一些预测变量,包括年龄、卡诺夫斯基功能状态、性别、疾病类型、精神药物,以及一些结果变量,包括OS和非复发死亡率(NRM)。移植前,36.4%的患者符合认知功能障碍的标准。研究发现年龄以及疾病类型(骨髓增生异常综合征[MDS]、骨髓增殖性疾病[MPD])是显著的预测因素。未发现认知功能障碍与OS或NRM之间存在显著关联。从移植前到移植后的纵向分析表明,HSCT后患者的认知功能有显著下降。值得注意的是,研究队列中有三分之一的患者在出院时出现认知功能障碍。相当一部分HSCT候选患者存在认知功能障碍,在该队列中,老年患者以及被诊断为MDS和MPD的患者风险最高。移植前关注认知功能障碍可能会提醒治疗团队注意那些需要加强监督、护理人员参与以及出院时转介至职业治疗的高风险病例。需要进行纵向随访研究,以阐明HSCT对认知功能障碍的具体影响以及认知功能障碍对移植结局的影响。